

2-Hydroxyethyl methacrylate (HEMA) 1% versus 2%

Gizem Kocabas | Norbertus A. Ipenburg | Anton C. de Groot  | Thomas Rustemeyer

Dermato-Allergology and Occupational Dermatology, Amsterdam University Medical Centers, Amsterdam, The Netherlands

Correspondence

Anton C. de Groot, Dermato-Allergology and Occupational Dermatology, Amsterdam University Medical Centers, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.

Email: antondegroot@planet.nl

2-Hydroxyethyl methacrylate (HEMA) is currently an important contact allergen,^{1,2} especially linked to the use of modern nail cosmetics in the female population.³ HEMA for patch testing is available in concentrations of 2% (Chemotechnique, Allergeaze) and 1% (Allergeaze). Most centres use 2%, which is also the concentration advised by the European Society of Contact Dermatitis as part of the European baseline series.⁴ However, in the standard series of the Deutschen Kontaktallergie-Gruppe (DKG), which is used in Germany, Austria and Switzerland, HEMA is present in the 1% concentration⁵ and this concentration is (or was, at least up to July 2019) also used at the Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.⁶ Comparative studies investigating whether one of these test concentrations performs better than the other appear not to have been done.

Between 17 October 2023 and 1 March 2024 we have patch tested 348 consecutive patients with HEMA 1% and HEMA 2% pet. reading the results on day (D)2 and D3 or D4, but not D7. There were 13 positive reactions to HEMA 2% (3.7%) and 9 to HEMA 1% (2.6%); of the latter group 8 also reacted to 2% pet. Of the 13 patients who tested positive for HEMA 2%, 5 (38%) would have been missed by only testing the lower concentration of 1% ($P < 0.001$ Fisher's exact test).

This appears to be the first indication that testing with HEMA 1% may fail to identify sensitization to this important methacrylate in a number of patients. Active sensitization to HEMA 2% is extremely rare,^{2,4,7} the test preparation does not commonly result in unacceptably strong reactions and 2% is the generally advised concentration for testing methacrylates. Therefore, a lower concentration would appear to have no advantages and may theoretically give rise to false-negative reactions. Our results in this small group of patients suggest that false-negative reactions do indeed occur, at least at the D3/D4 readings. As reactions to HEMA and other (meth)acrylates first

appearing after D4 are not uncommon, late readings might have affected the results in favour of HEMA 1% pet.; not having done this is an obvious weakness of our study. However, for practical reasons, most dermatologists do not routinely perform late readings and therefore results of D3 and D4 readings are important. We suggest that larger studies comparing HEMA 1% and 2% pet. be performed, which may be particularly interesting for those centres currently testing HEMA at 1% pet.

AUTHOR CONTRIBUTIONS

Gizem Kocabas: Data curation; investigation; visualization; writing – original draft. **Norbertus A. Ipenburg:** Formal analysis; writing – review and editing. **Anton C. de Groot:** Conceptualization; methodology; visualization; writing – original draft; writing – review and editing. **Thomas Rustemeyer:** Supervision; writing – review and editing.

CONFLICT OF INTEREST STATEMENT

The authors have no conflicts of interest.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available on request from the corresponding author.

ORCID

Anton C. de Groot  <https://orcid.org/0000-0002-6666-7292>

REFERENCES

- De Groot AC, Rustemeyer T. 2-Hydroxyethyl methacrylate (HEMA): a clinical review of contact allergy and allergic contact dermatitis-part 1. Introduction, epidemiology, case series and case reports. *Contact Dermatitis*. 2023;89(6):401-433. doi:10.1111/cod.14405

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2024 The Authors. *Contact Dermatitis* published by John Wiley & Sons Ltd.

2. De Groot AC, Rustemeyer T. 2-Hydroxyethyl methacrylate (HEMA): a clinical review of contact allergy and allergic contact dermatitis. Part 2. Cross- and co-sensitization, other skin reactions to HEMA, position of HEMA among (meth)acrylates, sensitivity as screening agent, presence of HEMA in commercial products and practical information on patch test procedures. *Contact Dermatitis*. 2024;90(1):1-16. doi:10.1111/cod.14430
3. Kocabas G, Steunebrink IM, de Groot A, Rustemeyer T. Results of patch testing 2-hydroxyethyl methacrylate (HEMA) in the European baseline series: a 4-year retrospective study. *Contact Dermatitis*. 2024; 90(5):466-469. doi:10.1111/cod.14488
4. Wilkinson SM, Gonçalo M, Aerts O, et al. The European baseline series and recommended additions: 2023. *Contact Dermatitis*. 2023;88(2): 87-92. doi:10.1111/cod.14255
5. Epikutantestreihen der Deutsche Kontaktallergie-Gruppe (DKG). DKG Standardreihe. Stand Juli 2023. Accessed April 5, 2024. <https://dkg.ivdk.org/testreihen.html#a001>
6. Havmose M, Thyssen JP, Zachariae C, Johansen JD. Contact allergy to 2-hydroxyethyl methacrylate in Denmark. *Contact Dermatitis*. 2020; 82(4):229-231. doi:10.1111/cod.13439
7. Goon AT, Bruze M, Zimerson E, et al. Correlation between stated and measured concentrations of acrylate and methacrylate allergens in patch-test preparations. *Dermatitis*. 2011;22(1):27-32.

How to cite this article: Kocabas G, Ipenburg NA, de Groot AC, Rustemeyer T. 2-Hydroxyethyl methacrylate (HEMA) 1% versus 2%. *Contact Dermatitis*. 2024;1-2. doi:10.1111/cod.14571